Henry Punzi

1.3k total citations
50 papers, 702 citations indexed

About

Henry Punzi is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Henry Punzi has authored 50 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cardiology and Cardiovascular Medicine, 19 papers in Endocrinology, Diabetes and Metabolism and 13 papers in Surgery. Recurrent topics in Henry Punzi's work include Blood Pressure and Hypertension Studies (34 papers), Hormonal Regulation and Hypertension (18 papers) and Sodium Intake and Health (11 papers). Henry Punzi is often cited by papers focused on Blood Pressure and Hypertension Studies (34 papers), Hormonal Regulation and Hypertension (18 papers) and Sodium Intake and Health (11 papers). Henry Punzi collaborates with scholars based in United States, Brazil and Germany. Henry Punzi's co-authors include Joel M. Neutel, Michael G. Shlipak, Alfred K. Cheung, Joachim H. Ix, William B. White, Walter T. Ambrosius, Vasantha Jotwani, Robert Dubiel, Ronit Katz and Alan H. Gradman and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Henry Punzi

45 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henry Punzi United States 17 413 215 180 123 105 50 702
Giacomina Loriga Italy 8 381 0.9× 146 0.7× 234 1.3× 101 0.8× 81 0.8× 11 604
Nitin Khosla United States 9 328 0.8× 257 1.2× 265 1.5× 109 0.9× 64 0.6× 14 637
Juan García‐Puig Spain 17 550 1.3× 307 1.4× 144 0.8× 94 0.8× 140 1.3× 45 1.0k
Ryusuke Kakiya Japan 12 396 1.0× 200 0.9× 343 1.9× 121 1.0× 154 1.5× 14 946
Frank A. Holtkamp Netherlands 6 275 0.7× 240 1.1× 281 1.6× 110 0.9× 54 0.5× 9 574
Chao Chu China 16 303 0.7× 149 0.7× 150 0.8× 150 1.2× 47 0.4× 75 731
S. J. L. Bakker Netherlands 9 439 1.1× 164 0.8× 111 0.6× 41 0.3× 72 0.7× 10 765
Jan A. Krikken Netherlands 13 329 0.8× 122 0.6× 235 1.3× 181 1.5× 75 0.7× 27 680
W. Marz Germany 10 314 0.8× 248 1.2× 146 0.8× 100 0.8× 136 1.3× 11 731
Joanna Niegowska Poland 6 759 1.8× 186 0.9× 138 0.8× 85 0.7× 95 0.9× 17 1.6k

Countries citing papers authored by Henry Punzi

Since Specialization
Citations

This map shows the geographic impact of Henry Punzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Punzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Punzi more than expected).

Fields of papers citing papers by Henry Punzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Punzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Punzi. The network helps show where Henry Punzi may publish in the future.

Co-authorship network of co-authors of Henry Punzi

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Punzi. A scholar is included among the top collaborators of Henry Punzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Punzi. Henry Punzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alcocer, Luis, Ernesto L. Schiffrin, Gregory D. Fink, et al.. (2025). Racial and Gender Discrimination When Tailoring Medical Management to Hypertension Treatment in Latin America. American Journal of Hypertension. 38(10). 739–747.
2.
Ahmad, Sarfaraz, Gagan Deep, Henry Punzi, et al.. (2024). Chymase Activity in Plasma and Urine Extracellular Vesicles in Primary Hypertension. SHILAP Revista de lepidopterología. 5(11). 1613–1622. 2 indexed citations
3.
Srinivasan, Dhivya, Güray Erus, Manjula Kurella Tamura, et al.. (2023). Intensive Blood Pressure Management Preserves Functional Connectivity in Patients with Hypertension from the Systolic Blood Pressure Intervention Randomized Trial. American Journal of Neuroradiology. 44(5). 582–588.
4.
Upadhya, Bharathi, Nicholas M. Pajewski, Michael V. Rocco, et al.. (2021). Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART. Hypertension. 77(5). 1571–1580. 14 indexed citations
5.
Ahmad, Sarfaraz, et al.. (2021). Newly developed radioimmunoassay for Human Angiotensin-(1–12) measurements in plasma and urine. Molecular and Cellular Endocrinology. 529. 111256–111256. 20 indexed citations
6.
Jotwani, Vasantha, Pranav S. Garimella, Ronit Katz, et al.. (2020). Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants. American Journal of Nephrology. 51(10). 797–805. 22 indexed citations
7.
Jotwani, Vasantha, Alexandra K. Lee, Michelle M. Estrella, et al.. (2019). Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease. American Journal of Nephrology. 49(5). 346–355. 17 indexed citations
8.
Rodríguez, Carlos J., Carolyn H. Still, Katelyn R Garcia, et al.. (2016). Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic Blood Pressure Intervention Trial. Journal of Clinical Hypertension. 19(2). 116–125. 14 indexed citations
9.
Lewin, Andrew, et al.. (2013). Nebivolol Monotherapy for Patients With Systolic Stage II Hypertension: Results of a Randomized, Placebo-Controlled Trial. Clinical Therapeutics. 35(2). 142–152. 9 indexed citations
10.
Punzi, Henry, et al.. (2012). Efficacy/Safety of Olmesartan Medoxomil Versus Losartan Potassium in Naïve Versus Previously Treated Subjects With Hypertension. Advances in Therapy. 29(6). 524–537. 9 indexed citations
11.
Punzi, Henry, et al.. (2011). Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. Journal of Clinical Hypertension. 13(6). 422–430. 9 indexed citations
12.
13.
14.
Kawata, Ariane K., Dennis A. Revicki, Roopal Thakkar, et al.. (2009). Flushing ASsessment Tool (FAST©). Clinical Drug Investigation. 29(4). 215–229. 18 indexed citations
15.
Kereiakes, Dean J., Joel M. Neutel, Henry Punzi, et al.. (2007). Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate. American Journal of Cardiovascular Drugs. 7(5). 361–372. 28 indexed citations
16.
White, William B., et al.. (2006). Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination With Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension. Journal of Clinical Hypertension. 8(9). 626–633. 35 indexed citations
17.
Punzi, Henry, et al.. (2004). Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study. Current Hypertension Reports. 6(2). 106–110. 21 indexed citations
18.
Gradman, Alan H., et al.. (1999). Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Clinical Therapeutics. 21(3). 442–453. 31 indexed citations
19.
Punzi, Henry. (1993). Safety update: Focus on cough. The American Journal of Cardiology. 72(20). H45–H48. 8 indexed citations
20.
Weir, Matthew R., et al.. (1992). A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension.. PubMed. 6(2). 133–8. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giacomina Loriga Breakdown of academic impact, for papers by Nitin Khosla Breakdown of academic impact, for papers by Juan García‐Puig Breakdown of academic impact, for papers by Ryusuke Kakiya Breakdown of academic impact, for papers by Frank A. Holtkamp Breakdown of academic impact, for papers by Chao Chu Breakdown of academic impact, for papers by S. J. L. Bakker Breakdown of academic impact, for papers by Jan A. Krikken Breakdown of academic impact, for papers by W. Marz Breakdown of academic impact, for papers by Joanna Niegowska
Rankless by CCL
2026